SCHEMBL1107928

SCHEMBL1107928

CC1(C)c2cc(-c3nnc(-c4cccc(-c5cccc(C(F)(F)F)c5)n4)s3)ccc2-c2ccc(-c3nnc(-c4cccc(-c5cccc(C(F)(F)F)c5)n4)s3)cc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 3/20 0.45
PIM3 Q86V86 3/20 0.45
CTSS P25774 1/20 0.43
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
KDM4E B2RXH2 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM1A O60341 1/20 0.38
F2RL3 Q96RI0 1/20 0.38
MAOB P27338 1/20 0.37
KMO O15229 1/20 0.37
EIF4E P06730 1/20 0.37
MAOA P21397 2/20 0.37
MAPT P10636 1/20 0.37
PIM2 Q9P1W9 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
GABRA1 P14867 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1107924 0.91 PIM1 (0.36) PIM1PIM3MAOBEIF4EPIM2
SCHEMBL1107942 0.86 CTSS (0.52) PIM1PIM3CTSSALDH1A1SMN1; SMN2
SCHEMBL1107938 0.86 CTSS (0.52) PIM1PIM3CTSSALDH1A1SMN1; SMN2
SCHEMBL1107869 0.85 PIM1 (0.46) PIM1PIM3ALDH1A1KDM4EMEN1
SCHEMBL1107914 0.84 CTSS (0.56) PIM1PIM3CTSSALDH1A1SMN1; SMN2
SCHEMBL1107948 0.84 PIM1 (0.41) PIM1PIM3PIM2
SCHEMBL1107936 0.83 GUSB (0.41) PIM1PIM3KDM4EMAPTPIM2
SCHEMBL1107873 0.83 CTSS (0.48) PIM1PIM3CTSSALDH1A1SMN1; SMN2
SCHEMBL1107923 0.83 CTSS (0.52) PIM1PIM3CTSSALDH1A1SMN1; SMN2
SCHEMBL1107910 0.82 PIM1 (0.37) PIM1PIM3F2RL3KMOEIF4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153277-B2 Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2009-04-30 US disclosed
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO., LTD. (JP) 2009-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090108750-A1 COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE OXA1L, SLCO4C1, SLCO2B1 PIM1 1477/4885PIM3 1919/4885CTSS 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.